TXMD
TherapeuticsMD Inc
NASDAQ: TXMD · HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC
$1.96
+1.52% today
Updated 2026-06-04
Market cap
$21.07M
P/E ratio
182.00
P/S ratio
6.28x
EPS (TTM)
$0.01
Dividend yield
—
52W range
$1 – $3
Volume
0.0M
WallStSmart proprietary scores
41
out of 100
Grade: D
Sell
Investment rating
5.3
Growth
C+7.0
Quality
B+3.0
Profitability
D4.0
Valuation
C4/9
Piotroski F-Score
Moderate
-33.9
Altman Z-Score
Distress
—
Industry rank
—
View all highly rated stocks (75+) →202 stocks currently score above 75
Price targets
Analyst target
$5.00
+155.10%
12-Month target
$0.07
-96.43%
Intrinsic (DCF)
—
Margin of safety
—
Price chart
Stock snapshot
Strengths
+ Free cash flow $936000.00 — positive
+ Revenue growth 84.20% QoQ
+ Debt/equity 0.18x — low leverage
Risks
- Altman Z -33.89 — distress zone
- P/E 182.00x — expensive valuation
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $69.96M | $1.30M | $1.76M | $3.02M | $3.35M |
| Net income | $112.00M | $-10.28M | $-2.18M | $-569000.00 | $95000.00 |
| EPS | — | — | — | — | $0.01 |
| Free cash flow | $-4.43M | $-96.28M | $732000.00 | $2.42M | $936000.00 |
| Profit margin | 160.08% | -789.40% | -123.85% | -18.83% | 5.34% |
Peer comparison
Smart narrative
TherapeuticsMD Inc trades at $1.96. representing a P/E of 182.00x trailing earnings. Our Smart Value Score of 41/100 indicates the stock is fair. The company scores 4/9 on the Piotroski F-Score. With an Altman Z-Score of -33.89, it sits in the distress. TTM revenue stands at $3.35M. with profit margins at 5.34%.
Frequently asked questions
What is TherapeuticsMD Inc's stock price?
TherapeuticsMD Inc (TXMD) trades at $1.96, on a P/E of 182.0x and a P/S of 6.3x. Those multiples show what the market is paying for each dollar of earnings and sales, which is the real starting point for judging whether the price is reasonable.
Is TherapeuticsMD Inc overvalued?
TherapeuticsMD Inc carries a Smart Value Score of 41/100 (Grade D), which we rate Sell. That score blends growth, quality, and valuation into one read.
What is the price target of TherapeuticsMD Inc (TXMD)?
The 12-month analyst consensus target is $5.00, about 155.1% above the current $1.96. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.
What is TherapeuticsMD Inc's revenue?
TherapeuticsMD Inc's trailing twelve-month revenue is $3.35M. Revenue scale anchors the valuation multiples and shows whether growth is reaching the top line, so it is best read alongside margin and growth trends to see if that revenue is getting more profitable over time.
Altman Z-Score?
TherapeuticsMD Inc's Altman Z-Score is -33.89, which places it in the distress. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.
Company info
SectorHEALTHCARE
IndustryDRUG MANUFACTURERS - SPECIALTY & GENERIC
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio6.28x
ROE0.66%
Beta0.58
50D MA$2.05
200D MA$1.80
Shares out0.01B
Float0.01B
Short ratio—
Avg volume0.0M
Performance
1 week—
1 month—
3 months—
YTD—
1 year—
3 years—
5 years—